Multiple Myeloma and Immunology: From Pathophysiology to Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 12
Special Issue Editor
2. Department of experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy
Interests: multiple myeloma immunotherapy; pathophysiology of multiple myeloma; multiple myeloma related bone disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Preclinical and clinical research in multiple myeloma has achieved impressive results in recent years. Multiple myeloma onset and development and its microenvironment have been extensively studied, allowing the critical switch from chemotherapy-based approaches to the combination of biological agents and immunotherapies.
Following this paradigm shift, outcomes of this still incurable disease have tremendously improved. Indeed, the aim of this issue is to provide a critical overview of the state-of-the-art of immunology preclinical studies and the latest immune-based therapy developments, with a special focus on the new combo treatments and the innovative T cell redirecting therapies.
Dr. Marco Rossi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma microenvironment
- immunotherapy
- T cell redirecting agents
- CAR-T in multiple myeloma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
